# Proteome-Wide Monitoring of Drug Action in Living Cells Using a Novel Label-Free Solvent-Based Shift Assay

**Authors:** Dominik Steinbrunn, Catalina Cepeleaga, Alexander Betz, Gözde Kibar, Melanie Holzner, Stefan K. Maier, Christin Zasada, Götz Hagemann, Stephan A. Sieber, Hannes Hahne

PMC · DOI: 10.1016/j.mcpro.2025.101444 · Molecular & Cellular Proteomics : MCP · 2025-11-05

## TL;DR

A new method called SPICE uses organic solvents to study drug effects on proteins in live cells, revealing drug targets and biological impacts.

## Contribution

SPICE is a novel label-free assay for proteome-wide drug action monitoring in living cells, detecting drug targets and downstream effects.

## Key findings

- SPICE detects drug-target interactions and secondary effects in live cells, unlike lysate-based methods.
- SPICE complements CETSA by providing distinct insights into drug mechanisms and target engagement.
- SPICE can identify degrader drug targets even when targets are being degraded.

## Abstract

Biophysical proteomics assays allow for proteome-wide, label-free monitoring of ligand-induced changes in protein structure and stability, offering insights into protein-ligand interactions and modulation of biophysical properties of cellular proteins. These assays exploit the principle that compound-induced alterations in structure or stability of proteins can be detected through changes in their susceptibility to denaturation. Here, we introduce solvent proteome profiling in cells (SPICE), which employs solvent-based denaturation of proteins under otherwise physiological conditions in intact cells. We characterized solvent-induced denaturation of proteins inside cells as distinct from that in cell extracts and validated SPICE by detecting known drug-target interactions for multiple compound classes. Our results indicate that SPICE, unlike experiments in cell extracts, also detects secondary compound-induced effects such as target profiles of drug metabolites, modulation of protein-protein interactions, and downstream signaling events. We further demonstrate complementarity of SPICE and cellular thermal shift assay, which both robustly detect the designated targets of well-characterized drugs and individually provide biologically meaningful and interpretable results. Finally, we show that SPICE can detect covalent drug-targets, compound-induced target-destabilization and stabilization of degrader drug targets despite their concurrent degradation.

•Organic solvents allow for protein denaturation in live cells.•SPICE allows for drug target identification in live cells.•SPICE allows to infer biological downstream effects of inhibition of a drugs target.•SPICE is complementary to CETSA.•Modified format detects degrader target engagement despite concurrent degradation.

Organic solvents allow for protein denaturation in live cells.

SPICE allows for drug target identification in live cells.

SPICE allows to infer biological downstream effects of inhibition of a drugs target.

SPICE is complementary to CETSA.

Modified format detects degrader target engagement despite concurrent degradation.

A method for solvent proteome profiling in cells has been developed. Protein denaturation by organic solvents in live cells was characterized and intracellular target engagement was detected for multiple compound classes. In contrast to lysate-based experiments, the method allowed to infer biological downstream effects of drug target inhibition. Denaturation profiling, target identification, and mechanism-of-action deconvolution provided complementary insights to the cellular thermal shift assay. Modification of the method enabled detection of intracellular target engagement despite concurrent degradation of target proteins.

## Full-text entities

- **Genes:** TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, TESC (tescalcin) [NCBI Gene 54997] {aka CHP3, TSC}, CLN5 (CLN5 lysosomal BMP synthase) [NCBI Gene 1203], RBM39 (RNA binding motif protein 39) [NCBI Gene 9584] {aka CAPER, CAPERalpha, FSAP59, HCC1, RNPC2}, MUL1 (mitochondrial E3 ubiquitin protein ligase 1) [NCBI Gene 79594] {aka C1orf166, GIDE, MAPL, MULAN, RNF218}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, PAF1 (PAF1 component of Paf1/RNA polymerase II complex) [NCBI Gene 54623] {aka F23149_1, PD2}, LEO1 (LEO1 component of Paf1/RNA polymerase II complex) [NCBI Gene 123169] {aka RDL}, Hdac1 (histone deacetylase 1) [NCBI Gene 433759] {aka HD1, Hdac1-ps, MommeD5, RPD3}, PPIL1 (peptidylprolyl isomerase like 1) [NCBI Gene 51645] {aka CGI-124, CYPL1, PCH14, PPIase, hCyPX}, RIPK2 (receptor interacting serine/threonine kinase 2) [NCBI Gene 8767] {aka CARD3, CARDIAK, CCK, GIG30, RICK, RIP2}, LMNB2 (lamin B2) [NCBI Gene 84823] {aka EPM9, LAMB2, LMN2, MCPH27}, DHFR (dihydrofolate reductase) [NCBI Gene 1719] {aka DHFR1, DYR}, RBX1 (ring-box 1) [NCBI Gene 9978] {aka BA554C12.1, RNF75, ROC1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, AKT1S1 (AKT1 substrate 1) [NCBI Gene 84335] {aka Lobe, PRAS40}, CLSPN (claspin) [NCBI Gene 63967], PPP3R1 (protein phosphatase 3 regulatory subunit B, alpha) [NCBI Gene 5534] {aka CALNB1, CNB, CNB1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, BRD4 (bromodomain containing 4) [NCBI Gene 23476] {aka CAP, CDLS6, FSHRG4, HUNK1, HUNKI, MCAP}, RPL4 (ribosomal protein L4) [NCBI Gene 6124] {aka L4, uL4}, PPIA (peptidylprolyl isomerase A) [NCBI Gene 5478] {aka CYPA, CYPH, HEL-S-69p}, TYMS (thymidylate synthetase) [NCBI Gene 7298] {aka DKCD, HST422, TMS, TS}, JMJD6 (jumonji domain containing 6, arginine demethylase and lysine hydroxylase) [NCBI Gene 23210] {aka PSR, PTDSR, PTDSR1}, FKBP8 (FKBP prolyl isomerase 8) [NCBI Gene 23770] {aka FKBP38, FKBPr38}, FECH (ferrochelatase) [NCBI Gene 2235] {aka EPP, EPP1, FCE}, CTSZ (cathepsin Z) [NCBI Gene 1522] {aka CTSX}, SPICE1 (spindle and centriole associated protein 1) [NCBI Gene 152185] {aka CCDC52, SPICE}, CIB1 (calcium and integrin binding 1) [NCBI Gene 10519] {aka CIB, CIBP, EV3, KIP1, PRKDCIP, SIP2-28}, ELOB (elongin B) [NCBI Gene 6923] {aka SIII, TCEB2}, LYN (LYN proto-oncogene, Src family tyrosine kinase) [NCBI Gene 4067] {aka JTK8, SAIDV, p53Lyn, p56Lyn}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, PRELID1 (PRELI domain containing 1) [NCBI Gene 27166] {aka CGI-106, PRELI, PX19, SBBI12}, FYN (FYN proto-oncogene, Src family tyrosine kinase) [NCBI Gene 2534] {aka SLK, SYN, p59-FYN}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, RNF181 (ring finger protein 181) [NCBI Gene 51255] {aka HSPC238}, EIF2A (eukaryotic translation initiation factor 2A) [NCBI Gene 83939] {aka CDA02, EIF-2A, MST089, MSTP004, MSTP089}, DCAF15 (DDB1 and CUL4 associated factor 15) [NCBI Gene 90379] {aka C19orf72}, MTR (5-methyltetrahydrofolate-homocysteine methyltransferase) [NCBI Gene 4548] {aka HMAG, MS, cblG}, PPIF (peptidylprolyl isomerase F) [NCBI Gene 10105] {aka CYP3, CyP-M, Cyp-D, CypD}, SORL1 (sortilin related receptor 1) [NCBI Gene 6653] {aka C11orf32, LR11, LRP9, SORLA, SorLA-1, gp250}, PPIB (peptidylprolyl isomerase B) [NCBI Gene 5479] {aka CYP-S1, CYPB, HEL-S-39, OI9, SCYLP}, BTK (Bruton tyrosine kinase) [NCBI Gene 695] {aka AGMX1, AT, ATK, BPK, IGHD3, IMD1}, EIF2AK2 (eukaryotic translation initiation factor 2 alpha kinase 2) [NCBI Gene 5610] {aka PKR, PPP1R83, PRKR}, IGF2R (insulin like growth factor 2 receptor) [NCBI Gene 3482] {aka CD222, CI-M6PR, CIMPR, M6P-R, M6P/IGF2R, MPR 300}, Hdac2 (histone deacetylase 2) [NCBI Gene 15182] {aka D10Wsu179e, YAF1, Yy1bp, mRPD3}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, DCLK2 (doublecortin like kinase 2) [NCBI Gene 166614] {aka CL2, CLICK-II, CLICK2, CLIK2, DCAMKL2, DCDC3}, BRD3 (bromodomain containing 3) [NCBI Gene 8019] {aka FSHRG2, ORFX, RING3L}, SORT1 (sortilin 1) [NCBI Gene 6272] {aka Gp95, LDLCQ6, NT3, NTR3}, PPP3CA (protein phosphatase 3 catalytic subunit alpha) [NCBI Gene 5530] {aka ACCIID, CALN, CALNA, CALNA1, CNA1, DEE91}, BRD2 (bromodomain containing 2) [NCBI Gene 6046] {aka BRD2-IT1, D6S113E, FSH, FSHRG1, FSRG1, NAT}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}, FKBP3 (FKBP prolyl isomerase 3) [NCBI Gene 2287] {aka FKBP-25, FKBP-3, FKBP25, PPIase}, LMNB1 (lamin B1) [NCBI Gene 4001] {aka ADLD, LMN, LMN2, LMNB, MCPH26}, VHL (von Hippel-Lindau tumor suppressor) [NCBI Gene 7428] {aka HRCA1, RCA1, VHL1, pVHL}, CDC73 (cell division cycle 73) [NCBI Gene 79577] {aka C1orf28, FIHP, HPTJT, HRPT1, HRPT2, HYX}, TBC1D2B (TBC1 domain family member 2B) [NCBI Gene 23102] {aka NEDSGO}, CUL2 (cullin 2) [NCBI Gene 8453], CTR9 (CTR9 component of Paf1/RNA polymerase II complex) [NCBI Gene 9646] {aka SH2BP1, TSBP, p150, p150TSP}
- **Diseases:** Huntington's disease (MESH:D006816), SIPP (MESH:D011488)
- **Chemicals:** water (MESH:D014867), Ibrutinib (MESH:C551803), MTX (MESH:D008727), Peptides (MESH:D010455), PGs (MESH:D010715), SDS (MESH:D012967), acetic acid (MESH:D019342), ethanol (MESH:D000431), metal (MESH:D008670), Methionine (MESH:D008715), SCIO-469 (MESH:C499748), MK-2206 (MESH:C548887), FA (MESH:C030544), DPBS (MESH:C012939), NP-40 (MESH:C010615), nitrogen (MESH:D009584), polyglutamates (MESH:D011099), acetonitrile (MESH:C032159), ATP (MESH:D000255), TEAB (MESH:C041737), bicinchoninic acid (MESH:C047117), cysteines (MESH:D003545), lipid (MESH:D008055), Indisulam (MESH:C439829), DMSO (MESH:D004121), folate (MESH:D005492), guanidinium chloride (MESH:D019791), MoA (-), Hepes (MESH:D006531), Vorinostat (MESH:D000077337), 5-methyl-tetrahydrofolate (MESH:C005984), CsA (MESH:D016572), hydroxylamine (MESH:D019811), urea (MESH:D014508), ammonium-bicarbonate (MESH:C027043), acetone (MESH:D000096)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), K562 — Homo sapiens (Human), Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_0004), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12802111/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12802111/full.md

## References

90 references — full list in the complete paper: https://tomesphere.com/paper/PMC12802111/full.md

---
Source: https://tomesphere.com/paper/PMC12802111